By The study found the Pfizer-BioNTech vaccine was 88% effective against symptomatic disease from the variant two weeks after the second dose.
The study found the Pfizer-BioNTech vaccine was 88% effective against symptomatic disease from the variant two weeks after the second dose.
Comments